论文部分内容阅读
对建立的肝癌H22荷瘤小鼠实体瘤体局部注射188Re后,采用CRCR-15型核素测量仪分别测定1和24h瘤体内放射性计数,计算188Re注入瘤体内24h内照射吸收剂量以及放射性滞留率。188Re-S注射至肿瘤内后,1和24h放射性药物滞留要高于单纯188Re注射液,188Re-S(0.1mCi)和(0.2mCi)组24h瘤体内照射剂量分别为159.78和361.52Gy。病理学检查结果:(1)模型组,瘤细胞生长旺盛,肿瘤内新生微血管丰富;(2)治疗组,瘤组织生长受到不同程度的抑制,瘤细胞生长稀疏,微血管减少,坏死区由瘤组织外周向中心渐进。电镜观察显示,188Re-S(0.1mCi)治疗组可见肿瘤组织细胞凋亡小体。将188Re-S置入小肝癌H22荷瘤小鼠实体瘤局部,在肿瘤局部形成高活度放射性聚集区,起到靶向治疗肿瘤作用的同时,可减少全身用量,以降低毒副作用。
The established tumor-bearing mice H22 tumor-bearing mice with local injection of 188Re, using CRCR-15 type nuclide measuring instrument were measured in 1 and 24 hours tumor radioactivity counts, calculated 188Re injected into the tumor within 24 hours of radiation absorbed dose and radioactive retention . After 188Re-S was injected into the tumor, the radioactive drug retention was higher at 1 and 24h than that of pure 188Re injection. The radiation doses of 188Re-S (0.1mCi) and (0.2mCi) group were 159.78 and 361.52Gy, respectively. Pathological examination results: (1) In the model group, the growth of tumor cells was vigorous and the new microvascular in the tumor was rich. (2) In the treatment group, the growth of tumor tissue was inhibited to some extent, the growth of tumor cells was sparse and the microvessels were reduced. Peripheral to the center of the gradual. Electron microscopy showed that apoptotic bodies were found in 188Re-S (0.1mCi) treated group. 188Re-S into small H22 tumor-bearing mice with solid tumor local tumor cells in the local formation of high activity radioactive accumulation zone, play a role in targeting the tumor while reducing systemic dosage to reduce side effects.